More on the Million Hearts RCT, ENRICH AF, TAVI vs SAVR, the Partner 3 and Evolut-low-risk trials, and myocardial viability are the topics John Mandrola, MD, covers in this week’s podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

I. Listener Feedback Million Hearts

CMS 'Million Hearts' CVD Risk Reduction Model Works



Oral Anticoagulation in ICH Patients With AF: New Data

-  Lancet Neurology Meta-analysis

-  ENRICH AF letter


Low-Risk TAVR Studies: Divergent Long-Term Results

-  Partner 3 Main Results

-  Partner 3 – Five Year

-  Original EVOLUT -LR

-  EVOLUT 3-year

-  EVOLUT -LR 4-year

III. Myocardial Viability

Viability-Guided PCI Doubted in Stable Severe CAD: REVIVED-BCIS2

-  Revived BCIS – Original paper

-  JAMA Cardiology Viability paper

-  STICH Viability Paper -

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

Questions or feedback, please contact [email protected]

Podden och tillhörande omslagsbild på den här sidan tillhör Medscape. Innehållet i podden är skapat av Medscape och inte av, eller tillsammans med, Poddtoppen.